Table 2 Angiographic and procedural characteristics of patients in the protamine and non-protamine groups

Multivessel disease

119 (74.4)

67 (72.8)

52 (76.5)

0.602

Lesion type B2/C

131 (81.9)

77 (83.7)

54 (79.4)

0.487

Number of stents (per patient)

2.4 ± 1.2

2.4 ± 1.3

2.4 ± 1.1

0.963

Treated lesion

 Unprotected left main disease

36 (22.5)

16 (17.4)

20 (29.4)

0.072

 ≥ 3 lesions

26 (16.3)

15 (16.3)

11 (16.2)

0.983

 Lesion length ≥ 60 mm

90 (56.3)

52 (56.5)

38 (55.9)

0.936

 Bifurcation treated with two-stent technique

33 (20.6)

19 (19.6)

14 (20.6)

0.873

 Chronic total occlusion

78 (48.8)

57 (62.0)

21 (30.9)

< 0.001

Stent

 Total length, mm

68.7 ± 39.2

68.9 ± 41.5

68.4 ± 36.1

0.930

 Minimal diameter, mm

2.89 ± 0.42

2.89 ± 0.42

2.89 ± 0.41

0.975

Drug eluting stent

 Everolimus

98 (61.3)

58 (63.0)

40 (58.8)

0.588

 Zotarlimus

49 (30.6)

29 (31.5)

20 (29.4)

0.775

 Sirolimus

15 (9.4)

12 (13.0)

3 (4.4)

0.098

 Biolimus

7 (4.4)

5 (5.4)

2 (2.9)

0.700

Use of IVUS

160 (100)

92 (100)

68 (100)

–

Sheath diameter

 7 Fr

144 (90.0)

80 (87.0)

64 (94.1)

0.219

 8 Fr

26 (16.3)

18 (19.6)

8 (11.8)

0.186

Heparin dose, unit

8762.5 ± 1835.1

8788.0 ± 1751.3

8727.9 ± 1955.5

0.838

ACT at the end of PCI, seconds

316.8 ± 73.7

320.2 ± 76.0

293.9 ± 53.0

0.252

Protamine dose, mg

–

45.9 ± 8.0

–

–

Procedural time, minutes

104.4 ± 56.1

108.2 ± 55.5

99.2 ± 57.0

0.317